Literature DB >> 31531787

Increasing age-related survival gap among patients with colorectal cancer: a population-based retrospective study.

Yang Feng1,2, Shaobo Mo1,2, Weixing Dai1,2, Qingguo Li3,4, Guoxiang Cai5,6, Sanjun Cai7,8.   

Abstract

BACKGROUND: Survival for patients with colorectal cancer (CRC) has improved over the past decades. However, it is unclear whether older patients have benefited to the same extent as younger patients.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) 9 registries database was queried for CRC patients from 1975 to 2009. We presented yearly data for survival with overlying loess-smoothing lines across all age groups. Another cohort was created using the SEER 18 registries database for patients diagnosed with CRC from 1973 to 2014. Yearly data for surgery-performed rate, stage proportion, and multivariate hazard ratio were performed with overlying smoothing lines across all age groups.
RESULTS: In the analysis SEER 9, 5-year cause-specific survival (CSS) of patients aged ≤ 54, 55-64, and 65-74 years showed robust increase since 1975; however, the survival of patients aged 75-84 years remained low despite modest improvement, and patients aged 85 or older even showed no survival gains since 1990. In the analysis of SEER 18, there has been a steady increase in the survival of patients aged ≤ 54, 55-64, 65-74, and 75-84 years as time period advanced; however, of CRC patients aged ≥ 85 years, the survival curves of period 1990-1999 and 2000-2012 could not be distinguished from each other presented with negligibly a small gap from the curve of 1980-1989.
CONCLUSIONS: The strong interaction between age and year of diagnosis implies that older patients have benefited less over time than younger patients, especially for patients aged ≥ 85 years.

Entities:  

Keywords:  Cause-specific survival; Colorectal cancer; Loess-smoothing lines; Older patients

Mesh:

Year:  2019        PMID: 31531787     DOI: 10.1007/s10147-019-01538-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  44 in total

1.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Authors:  David Cunningham; Istvan Lang; Eugenio Marcuello; Vito Lorusso; Janja Ocvirk; Dong Bok Shin; Derek Jonker; Stuart Osborne; Niko Andre; Daniel Waterkamp; Mark P Saunders
Journal:  Lancet Oncol       Date:  2013-09-10       Impact factor: 41.316

2.  Raltitrexed, a new drug for advanced colorectal cancer.

Authors:  G M Mead
Journal:  Lancet       Date:  1996-06-08       Impact factor: 79.321

3.  United States Life Tables, 2013.

Authors:  Elizabeth Arias; Melonie Heron; Jiaquan Xu
Journal:  Natl Vital Stat Rep       Date:  2017-04

Review 4.  Comprehensive geriatric assessment for older adults admitted to hospital.

Authors:  Graham Ellis; Martin A Whitehead; Desmond O'Neill; Peter Langhorne; David Robinson
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

5.  Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival.

Authors:  Chung-Yuan Hu; Christina E Bailey; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry W Feig; George J Chang
Journal:  JAMA Surg       Date:  2015-03-01       Impact factor: 14.766

6.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Authors:  Niall C Tebbutt; Kate Wilson; Val J Gebski; Michelle M Cummins; Diana Zannino; Guy A van Hazel; Bridget Robinson; Adam Broad; Vinod Ganju; Stephen P Ackland; Garry Forgeson; David Cunningham; Mark P Saunders; Martin R Stockler; Yujo Chua; John R Zalcberg; R John Simes; Timothy J Price
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

Authors:  Stephanie R Land; Jacek A Kopec; Reena S Cecchini; Patricia A Ganz; H Samuel Wieand; Linda H Colangelo; Kate Murphy; J Philip Kuebler; Thomas E Seay; Burton M Needles; James D Bearden; Lauren K Colman; Keith S Lanier; Eduardo R Pajon; David Cella; Roy E Smith; Michael J O'Connell; Joseph P Costantino; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

8.  Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer.

Authors:  H Sorbye; M Cvancarova; C Qvortrup; P Pfeiffer; B Glimelius
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

9.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

10.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Authors:  Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.